… Patients have entered a long-term follow-up, where graft and patient survival along with a …
graft alteration will be assessed ( 18–20 ). In conclusion, prophylaxis with valganciclovir …

… valganciclovir prophylaxis versus preemptive therapy. After 1 year, the rates of CMV infection
and CMV disease were significantly lower in the prophylaxis … of valganciclovir prophylaxis …

… allograft recipients managed prophylactically or preemptively for CMV showed that both
treatments were equally effective in the combined prevention of acute rejection, graft … allograft …

… with a functioning graft; the only exception was one patient in the valacyclovir group who
was … has shown that valganciclovir prophylaxis in renal transplant recipients is not superior to …

… be at higher risk of developing CMV disease while they were receiving VGC prophylaxis in
comparison with recipients of other allografts? There are several potential explanations: the …

… ’ valganciclovir prophylaxis (900 mg once daily) in 326 high‐risk (D+/R–) kidney allograft
recipients… In conclusion, this study demonstrates that extending valganciclovir prophylaxis (900 …

… (24) studied viral resistance in SOT recipients receiving valganciclovir prophylaxis for 100
days. In that study, no GCV-resistance mutations were detected in CMV isolates obtained from …

… CMV DNA monitoring with universal 3-month valacyclovir prophylaxis in RTx recipients. …
cases of graft failure in the valacyclovir group because of severe AMR and chronic allograft …

… transplant recipients directly comparing valganciclovir prophylaxis and … valganciclovir
prophylaxis versus preemptive therapy with the primary outcome being the incidence of allograft …

… (HTx) recipients treated according to current prophylactic and … and valganciclovir prophylaxis,
a significant effect of CMV infection on the risk of CAV was seen only among HTx recipients …